Using cDNA microarray to assess Parkinson's disease models and the effects of neuroprotective drugs

Trends in Pharmacological Sciences

Volumn 24, Issue 4, 2003, Pages 184-191

  Mandel, Silvia ^a   Weinreb, Orly ^a   Youdim, Moussa B H ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ANTIOXIDANT; APOMORPHINE; CYCLIN B; DOPAMINE; EPIGALLOCATECHIN GALLATE; INTERLEUKIN 1BETA; MELATONIN; MESSENGER RNA; NEUROPROTECTIVE AGENT; NEUROTOXIN; PROTEIN BCL 2; PROTEIN BCL XL; TYROSINE 3 MONOOXYGENASE;

DEGENERATIVE DISEASE; DNA MICROARRAY; DOPAMINERGIC NERVE CELL; DRUG ACTIVITY; DRUG EFFECT; GENE EXPRESSION PROFILING; GENOMICS; GENOTYPE; HUMAN; NERVE CELL DEGENERATION; NEUROPROTECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; SEQUENCE HOMOLOGY;

EID: 0037386720     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(03)00067-1     Document Type: Review

References (53)

1. Marsden C.D. Basal ganglia disease. Lancet. 2:1982;1141-1147.
2. Spillantini M.G., et al. Alpha-synuclein in Lewy bodies. Nature. 388:1997;839-840.
3. Shimura H., et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat. Genet. 25:2000;302-305.
4. Polymeropoulos M.H. Genetics of Parkinson's disease. Ann. New York Acad. Sci. 920:2000;28-32.
5. Olanow C.W., Youdim M.B. Iron and neurodegeneration: prospects for neuroprotection. Olanow C.W., et al. Neurodegeneration and Neuroprotection in Parkinson's Disease. 1996;55-69 Academic Press.
6. Halliwell B. Reactive oxygen species and the central nervous system. J. Neurochem. 59:1992;1609-1623.
7. Gotz M.E., et al. Oxidative stress: free radical production in neural degeneration. Pharmacol. Ther. 63:1994;37-122.
8. Riederer P., et al. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem. 52:1989;515-520.
9. Mizuno Y., et al. Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem. Biophys. Res. Commun. 163:1989;1450-1455.
10. Saggu H., et al. A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra. J. Neurochem. 53:1989;692-697.
11. Sofic E., et al. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci. Lett. 142:1992;128-130.
12. Jellinger K.A. The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease. Drugs Aging. 14:1999;115-140.
13. Ye F.Q., et al. Basal ganglia iron content in Parkinson's disease measured with magnetic resonance. Mov. Disord. 11:1996;243-249.
14. Lan J., Jiang D.H. Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice. J. Neural Transm. 104:1997;469-481.
15. Mandel S., et al. cDNA microarray to study gene expression of dopaminergic neurodegeneration and neuroprotection in MPTP and 6-hydroxydopamine models: implications for idiopathic Parkinson's disease. J. Neural Transm. Suppl. 60:2000;117-124.
16. Linazasoro G. Neuroprotection in Parkinson's disease: love story or mission impossible? Expert Rev. Neurotherapeutics. 2:2002;403-416.
17. Burns R.S., et al. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4- phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. U. S. A. 80:1983;4546-4550.
18. Chiueh C.C., et al. Role of dopamine autoxidation, hydroxyl radical generation, and calcium overload in underlying mechanisms involved in MPTP-induced parkinsonism. Adv. Neurol. 60:1993;251-258.
19. Davis G.C., et al. Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res. 1:1979;249-254.
20. Mendez J.S., Finn B.W. Use of 6-hydroxydopamine to create lesions in catecholamine neurons in rats. J. Neurosurg. 42:1975;166-173.
21. Kostrzewa R.M., Harper J.W. Effect of 6-hydroxydopa on catecholamine-containing neurons in brains of newborn rats. Brain Res. 69:1974;174-181.
22. Guilarte T.R. Is methamphetamine abuse a risk factor in parkinsonism? Neurotoxicology. 22:2001;725-731.
23. Shastry B.S. Parkinson disease: etiology, pathogenesis and future of gene therapy. Neurosci. Res. 41:2001;5-12.
24. Maruyama W., et al. Neuroprotection by propargylamines in Parkinson's disease. Suppression of apoptosis and induction of prosurvival genes. Neurotoxicol. Teratol. 24:2002;675-682.
25. Mirnics K., et al. Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron. 28:2000;53-67.
26. Whitney L.W., et al. Analysis of gene expression in mutiple sclerosis lesions using cDNA microarrays. Ann. Neurol. 46:1999;425-428.
27. Colangelo V., et al. Gene expression profiling of 12633 genes in Alzheimer hippocampal CA1: transcription and neurotrophic factor down-regulation and up-regulation of apoptotic and pro-inflammatory signaling. J. Neurosci. Res. 70:2002;462-473.
28. Ginsberg S.D., et al. Expression profile of transcripts in Alzheimer's disease tangle-bearing CA1 neurons. Ann. Neurol. 48:2000;77-87.
29. Grunblatt E., et al. Gene expression analysis in MPTP mice model of Parkinson's disease using cDNA microarray. J. Neurochem. 78:2001;1-12.
30. Grunblatt E., et al. Apomorphine protects against MPTP-induced neurotoxicity in mice. Mov. Disord. 14:1999;612-618.
31. Gassen M., et al. Apomorphine is a potent radical scavenger and protects cultured pheochromocytoma cells from 6-OHDA and H2O2-induced cell death. Adv. Pharmacol. 42:1998;320-324.
32. Grunblatt E., et al. Effects of R-apomorphine and S-apomorphine on MPTP-induced nigro-striatal doamine neuronal loss. J. Neurochem. 77:2001;146-156.
33. Brown V.M., et al. Multiplex three-dimensional brain gene expression mapping in a mouse model of Parkinson's disease. Genome Res. 12:2002;868-884.
34. Napolitano M., et al. Experimental parkinsonism modulates multiple genes involved in the transduction of dopaminergic signals in the striatum. Neurobiol. Dis. 10:2002;387-395.
35. Cadet J.L., et al. Temporal profiling of methamphetamine-induced changes in gene expression in the mouse brain: evidence from cDNA array. Synapse. 41:2001;40-48.
36. Jayanthi S., et al. Methamphetamine causes differential regulation of pro-death and anti- death Bcl-2 genes in the mouse neocortex. FASEB J. 15:2001;1745-1752.
37. Xie T., et al. Changes in gene expression linked to methamphetamine-induced dopaminergic neurotoxicity. J. Neurosci. 22:2002;274-283.
38. Berding G., et al. Resting regional cerebral glucose metabolism in advanced Parkinson's disease studied in the off and on conditions with [(18)F]FDG-PET. Mov. Disord. 16:2001;1014-1022.
39. Mandel S., et al. Early and late gene changes in MPTP mice model of Parkinson's disease employing cDNA microarray. Neurochem. Res. 27:2002;1231-1243.
40. Mandel, S. et al. Neuroprotective strategies in Parkinson's disease: an update on progress. CNS Drugs (in press).
41. Levites Y., et al. Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration. J. Neurochem. 78:2001;1073-1082.
42. Maimone D., et al. Pharmacogenomics of neurodegenerative diseases. Eur. J. Pharmacol. 413:2001;11-29.
43. Mandel S., et al. Molecular events in dopaminergic neurodegeneration and neuroprotection in MPTP model of parkinson's disease employing cDNA microarray. Miller A.C., et al. Brain Disease. 2001;Martin Dunitz.
44. Levites Y., et al. Involvement of protein kinase C activation and cell survival/cell cycle genes in green tea polyphenol (-)-epigallocatechin-3-gallate neuroprotective action. J. Biol. Chem. 277:2002;30574-30580.
45. Weinreb, O. et al. CDNA gene expression profile homology of antioxidants and their anti-apoptotic and pro-apoptotic activities in human neuroblastoma cells. FASEB J. (in press).
46. Luo Z., Geschwind D.H. Microarray applications in neuroscience. Neurobiol. Dis. 8:2001;183-193.
47. Eberwine J., et al. Analysis of gene expression in single live neurons. Proc. Natl. Acad. Sci. U. S. A. 89:1992;3010-3014.
48. Emmert-Buck M.R., et al. Laser capture microdissection. Science. 274:1996;998-1001.
49. Freed W.J., Vawter M.P. Microarrays: applications in neuroscience to disease, development, and repair. Restor. Neurol. Neurosci. 18:2001;53-56.
50. Expression profiling within the central nervous system. Neurochem. Res. 2002;27.
51. Pasinetti G.M., Ho L. From cDNA microarrays to high-throughput proteomics. Implications in the search for preventive initiatives to slow the clinical progression of Alzheimer's disease dementia. Restor. Neurol. Neurosci. 18:2001;137-142.
52. Jayanthi S., et al. Methamphetamine causes coordinate regulation of Src, Cas, Crk, and the Jun N-terminal kinase-Jun pathway. Mol. Pharmacol. 61:2002;1124-1131.
53. Williams R.W. Mapping genes that modulate brain development: a quantitative genetic approach. Goffinet A.F., Rakic P. Mouse Brain Development. 2000;21-49 Springer-Verlag.